Form 4: Moderna Director Noubar Afeyan Sells Shares Under 10b5-1 Trading Plan

Noubar Afeyan, a director at Moderna, sold shares of the company's common stock on June 12, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On June 12, 2024, Noubar Afeyan, a director of Moderna, sold multiple blocks of Moderna's common stock.
• The sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on February 27, 2023, and amended on November 7, 2023.
• The transactions involved multiple sales at varying weighted average prices, ranging from $142.9696 to $150.24 per share.
• The total number of shares sold was 17,001.
• Following the reported transactions, Afeyan directly owns 2,314,015 shares of Moderna common stock.
• Afeyan also has indirect ownership through Flagship Ventures Fund IV, L.P. (3,880,328 shares), Flagship Ventures Fund IV-Rx, L.P. (747,897 shares), and Flagship Pioneering, Inc. (3,924 shares).

Sentiment

Score: 5

Explanation: The document is a standard SEC filing related to stock sales by a company director. It doesn't inherently convey positive or negative sentiment, as it simply reports transactions executed under a pre-existing trading plan.

Future Outlook

The reporting person will likely continue to make sales under the Rule 10b5-1 trading plan.

Industry Context

Insider sales are a common occurrence, and the use of a 10b5-1 plan suggests the sales were pre-planned and not based on any specific non-public information.

Stakeholder Impact

• The stock sales could exert downward pressure on the stock price, potentially impacting shareholders.
• The sales do not appear to have any immediate impact on employees, customers, suppliers, or creditors.

Key Dates